Oncology News

AMSTERDAM — When adjusted for age and severity of liver disease, occurrence and recurrence of hepatocellular carcinoma after curing hepatitis C virus showed no difference between treatment with interferon or direct-acting antivirals, according to an expert at the International Liver Congress.

As we continue to see the success of direct-acting antiviral therapy in treating hepatitis C virus, we must be aware of any potential complications from the underlying liver disease after successful treatment, especially hepatocellular carcinoma.

The FDA authorized marketing of 23andMe Personal Genome Service Genetic Health Risk tests for 10 diseases and conditions, including Alzheimer’s disease, Parkinson’s disease and celiac disease.

The FDA granted orphan drug designation to Yeliva for the treatment of cholangiocarcinoma, according to the drug’s manufacturer.

ArQule and its partner Kyowa Hakko Kirin announced top-line results of the JET-HCC phase 3 trial for tivantinib, which did not meet its primary endpoint of progression-free survival, according to a company statement.

Overall cancer death rates continued to decrease in men, women and children among all racial and ethnic groups, according to the Annual Report to the Nation on the Status of Cancer.

Post-hepatectomy overall and hepatocellular carcinoma recurrence-free survival rates were significantly higher in patients with hepatitis C who achieved sustained virologic response with pegylated IFN plus ribavirin treatment compared with patients who did not.

Researchers reviewed the WHO database from 1990 to 2014 to update global trends of hepatocellular mortality and predict trends in rates in Europe, the United States and Japan, according to a recently published study.

A high BMI in young adult men was associated with an increased risk for developing severe liver disease and hepatocellular carcinoma, particularly in patients who later developed type 2 diabetes, according to recently published study results.

The Fibrolamellar Cancer Foundation awarded a $600,000 grant to Sanford Simon, PhD, head of the Laboratory of Cellular Biophysics at Rockefeller University, New York, to develop a therapy for fibrolamellar hepatocellular carcinoma, according to a press release.